Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety

Behavioural Brain Research

Volumn 140, Issue 1-2, 2003, Pages 203-214

  Nic Dhonnchadha, Bríd Áine ^a   Bourin, Michel ^a   Hascoët, Martine ^a  

^a Laboratoire Pharmacologie et GIS Medicament   (France)

Author keywords

5 HT2 Receptor agonists; 5 HT2 Receptor antagonists; Anxiety; EPM; FPT; L D paradigm

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4,5,7A,8,9,10,11,11A OCTAHYDRO 10 METHYL 7H INDOLO[1,7 BC][2,6]NAPHTHYRIDINE; 8 [4 (5 AMINO 2,4 DIMETHOXYBENZOYL)BUTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; 8 [5,2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4,5]DECANE 2,4 DIONE; EPLIVANSERIN; KETANSERIN; SEROTONIN 2 AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; LIGHT DARK CYCLE; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

AMPHETAMINES; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLAMINES; INDOLES; KETANSERIN; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; NAPHTHYRIDINES; PIPERAZINES; PSYCHOMOTOR PERFORMANCE; PYRIDINES; REACTION TIME; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SPIRO COMPOUNDS; SULFONAMIDES; THIOPHENES;

EID: 0037452851     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00311-X     Document Type: Article

References (87)

1. 2C receptor protein in human and rat brain using specific antisera. Neuropharmacology. 34:1995;1635-1645.
2. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
3. 2 receptor subtypes: a family re-united? TIPS. 105:1995;105-110.
4. 2B receptors. Behav. Brain Res. 73:1996;149-152.
5. Beckett S.R., Aspley S., Graham M., Marsden C.A. Pharmacological manipulations of ultrasound induced defence behaviour in the rat. Psychopharmacology. 127:1996;384-390.
6. 1B characterising agents in the mouse elevated plus maze. Life Sci. 47:1990;195-203.
7. Berg K.A., Clarke W.P., Sailstad C., Saltzman A., Maayani S. Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol. Pharmacol. 46:1994;477-484.
8. Berg K.A., Maayani S., Goldfarb J., Scarmellini C., Leff P., Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54:1998;94-104.
9. Boissier J.R., Simon P. Action de la caféine sur la motilité spontanée de la souris. Arch. Int. Pharmacodyn. 158:1965;212-221.
10. Boissier J.R., Simon P., Aron C. A new method for rapid screening of minor tranquillizers in mice. Eur. J. Pharmacol. 4:1968;145-151.
11. 2C receptors. Br. J. Pharmacol. 115:1995;622-628.
12. 2C receptor antagonist. Neuropharmacology. 36:1997;621-629.
13. 2C receptors in rodent models of potential anxiolytic properties. Behav. Pharmacol. 9:1998;S18-19.
14. Cheng C.H.K., Costall B., Kelly M.E., Naylor R.J. Actions of 5-hydroxytryptophan to inhibit and disinhibit mouse behaviour in the light/dark test. Eur. J. Pharmacol. 255:1994;39-49.
15. Chopin P., Briley M. Animal models of anxiety: the effect of compounds that modify serotonergic function. TIPS. 8:1987;383-388.
16. Costall B., Naylor R.J. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br. J. Pharmacol. 116:1995;2989-2999.
17. 4 receptor antagonists to modify drug induced disinhibitory effects in the mouse light/dark test. Br. J. Pharmacol. 122:1997;1105-1108.
18. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behaviour for the anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav. 13:1980;167-170.
19. 1C receptors. TIPS. 11:1990;181-182.
20. Custódio-Teixeira R., Zangrossi H., Graeff F.G. Behavioural effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol. Biochem. Behav. 65:2000;571-576.
21. Den Boer J.A., Westerberg H.G.M. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology. 102:1990;85-94.
22. 2B receptor agonist BW 723C86 produces anxiolysis on the elevated plus maze in the rat. Br. J. Pharmacol. 116:1995;331.
23. 2B receptor protein in the rat central nervous system. Neuroscience. 76:1997;323-329.
24. 2 and stomach fundus serotonin receptor genes. Neuroreport. 3:1992;345-348.
25. Gao B., Cutler M.G. Effect of acute and subchronic administration of ritanserin on the social behaviour of mice. Neuropharmacology. 32:1993;265-272.
26. Geller I., Seifter J. The effects of meprobamate, barbituates, D-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia. 1:1960;374-385.
27. Germine M., Goddard A.W., Woods S.W., Charney D.S., Heninger G.R. Anger and anxiety responses to m-chlorophenylpiperazine in generalised anxiety disorder. Biol. Psychiatry. 32:1992;457-461.
28. 2C receptors but not by sympathomimetic effects. Neuropharmacology. 33:1994;457-465.
29. Goldberg M.E., Manian A.A., Efron D.H. A comparative study of certain pharmacological responses following acute and chronic administration of chloradiazepoxide. Life Sci. 6:1969;481-491.
30. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 732:1996;145-153.
31. Graeff F.G., Audi E.A., Almeida S.S., Graeff E.O., Hunziker M.H.L. Behavioural effects of 5-HT receptor ligands in the aversive brain stimulation, elevated plus-maze and learned helplessness tests. Neurosci. Biobehav. Rev. 14:1990;501-506.
32. Graeff F.G., Netto C.F., Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23:1998;237-246.
33. Graeff F.G., Silveira M.C.L., Nogueira R.L., Audi E.A., Oliveira R.M.W. Role of the amygdala and periqueductal gray in anxiety and panic. Behav. Brain Res. 58:1993;123-131.
34. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more then 30 years of research. Pharmacol. Ther. 65:1995;319-395.
35. Griebel G. Variability in the effects of 5-HT related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Pol. J. Pharmacol. 48:1996;129-136.
36. Griebel G., Blanchard D.C., Jung A., Lee J.C., Masuda C.K., Blanchard R.J. Further evidence that the mouse defence test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology. 34:1995;1625-1633.
37. 2C receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology. 36:1997;793-802.
38. Guimarãres F.S., Mbaya P.S., Deakin F.W. Ritanserin facilitates anxiety in a simulated public-speaking paradigm. J. Psychopharmacol. 11:1997;225-231.
39. Handley S.L., McBlane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology. 112:1993;13-20.
40. Hascoët M., Bourin M. A new approach to the light/dark procedure in mice. Pharmacol. Biochem. Behav. 60:1998;645-653.
41. Hascoët M., Bourin M., Nic Dhonnchadha B.Á. The mouse light-dark paradigm: a review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;141-166.
42. Hetem L.A., De Souza C.J., Guimarães F.S., Zuardi A.W., Graeff F.G. D-Fenfluramine reduces anxiety by simulated public speaking. Braz. J. Med. Biol. Res. 26:1993;971-974.
43. Hetem L.A., De Souza C.J., Guimarães F.S., Zuardi A.W., Graeff F.G. Effect of D-fenfluramine on human experimental anxiety. Psychopharmacology. 127:1996;276-282.
44. 3 receptor antagonists. Psychopharmacology. 104:1991;545-551.
45. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A. International union of pharmacology classification of receptors of 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-204.
46. Iversen S.D. 5-HT and anxiety. Neuropharmacology. 23:1984;1553-1560.
47. 2C receptor agonists in an animal model of panic disorder. Eur. J. Neuropharmacol. 6:1996;108.
48. Jenck F., Moreau J.-L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res. 57:1995;181-191.
49. 2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur. Neuropsychopharmacol. 8:1998;161-168.
50. 2C receptor agonist, in three animal models of anxiety. Eur. J. Pharmacol. 387:2000;197-204.
51. 1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology. 107:1992;379-384.
52. 2B receptor agonist, BW 723C86, on three rat models of anxiety. Br. J. Pharmacol. 117:1996;1443-1448.
53. 2B receptor mediated. Neuropharmacology. 37:1998;1603-1610.
54. 1C receptor antagonists. Eur. J. Pharmacol. 164:1989;445-454.
55. 2B receptor antagonist with anxiolytic properties. Br. J. Pharmacol. 117:1996;427-434.
56. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology. 114:1994;90-96.
57. Kilts C.D., Commissaris R.L., Cordon J.J., Rech R.H. Lack of central 5-hydroxytryptamine influence on the anticonflict activity of diazepam. Psychopharmacology. 78:1982;156-164.
58. Klein E., Zohar J., Geraci M.F., Murphy D.L., Uhde T.W. Anxiogenic effects of mCPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol. Psychiatry. 30:1991;973-984.
59. Konstandi M., Johnson E., Lang M.A., Malamas M., Marselos M. Noradrenaline, dopamine, serotonin: different effects of psychological stress on brain biogenic amines in mice and rats. Pharmacol. Res. 41:(3):2000;341-346.
60. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
61. Martin P. Animal models sensitive to anti-anxiety agents. Acta. Psychiatry Scand. 98:1998;74-80.
62. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 286:1998;913-924.
63. 2C receptor agonists and antagonists in animal models of anxiety. Eur. Neuropsychopharm. Abstr. 5:1995;S17-25.
64. Menard J., Treit D. Lateral and medial septal lesions reduce anxiety in the plus-maze and probe burying tests. Physiol. Behav. 60:1996;845-853.
65. Menard J., Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 23:1999;591-613.
66. Misslin R., Belzung C., Vogel E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Process. 8:1989;119-132.
67. 2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharm. Biochem. Behav. 58:1997;1051-1057.
68. Nogueira R.L., Graeff F.G. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol. Biochem. Behav. 52:1995;1-6.
69. Onaivi E.S., Bishop-Robinson C., Darmani N.A., Sanders-Bush E. Behavioural effects of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus maze test. Life Sci. 57:1995;2455-2466.
70. Pazos A., Cortés R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in rat brain. II: Serotonin-2 receptors. Brain Res. 346:1985;231-249.
71. 2C receptors. Mol. Brain Res. 23:1994;163-178.
72. Racagni G. Current biological hypotheses of anxiety. Sartorius N., et al. Anxiety-Psychobiological and Clinical Perspectives. 1990;Hemisphere, New York.
73. Robichaud R.C., Slede K.L. The effects of p-chlorophenylalanine on experimentally induced conflict in the rat. Life Sci. 8:1969;965-969.
74. Rodgers R.J., Cao B.J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30:1997;289-304.
75. Rodgers R.J.R., Cole J.C.J., Cobain M.R.M., Daly P.P., Doran P.J.P., Eells J.R.J., Wallis P.P. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav. Pharmacol. 3:1992;621-634.
76. Rodgers R.J., Johnson N.J.T., Norton S.J., Cole J.C. Effects of ritanserin and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: an ethopharmacological study. J. Psychopharmacol. 9:1995;38-42.
77. 2C): where structure meets function. Pharmacol. Ther. 79:1998;231-257.
78. Sánchez C. Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white test box. Pharmacol. Toxicol. 77:1995;71-78.
79. Scorza M.C., Reyes-Parada M., Silveira R., Viola H., Medina J.H., Viana M.B., Zangrossi H., Graeff F.G. Behavioural effects of the putative anxiolytic (±)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice. Pharmacol. Biochem. Behav. 54:1996;353-361.
80. Setem J., Pinheiro A.P., Motta V.A., Morato S., Cruz A.P.M. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus maze. Pharmacol. Biochem. Behav. 62:1999;515-521.
81. Shanks N., Zalcman S., Zacharko R.M., Anisman H. Alterations of central norepinephrine, dopamine and serotonin in several strains of mice following acute stressor exposure. Pharmacol. Biochem. Behav. 38:1991;69-75.
82. 2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7-dihydroxytryptamine. Synapse. 27:1997;45-56.
83. 3 receptor antagonists. Neuropharmacology. 32:1993;987-993.
84. 2C receptor inactivation. J. Psychopharmacol. 10:1996;A56.
85. Umezu T. Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn. J. Pharmacol. 80:1999;111-118.
86. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
87. Witkin J.M., Perez L.A. Comparison of effects of buspirone and gepirone with benzodiazepines and antagonists of dopamine and serotonin receptors on punished behaviour of rats. Behav. Pharmacol. 1:1989;247-254.